Myocet® in Children With Relapsed or Refractory Non-brainstem Malignant Glioma

Inclusion Criteria: * Patients having received at least one cycle of chemotherapy after radiotherapy * Patients having grade III or IV (WHO) glioma, not localized in brainstem * Tumor measurable with magnetic resonance imaging * Absence of other concomitant anti-cancer treatments * Absence of chemotherapy for 4 weeks; 6 weeks if nitrosourea * Good general health and nutritional status according to NCI-CTC scale (version 3) (appendix 6) * Lansky score \> 50% or Karnofsky \> 50 in children older than 12 years * Absence of organ toxicity (grade \> 2 according to NCI-CTC criteria (version 3) * Hematology: polynuclear neutrophil count \> 1.0 x 109/l * Hematology: platelet count \> 100 x 109/l * Liver function: bilirubinemia \< 1.5 normal value * Liver function: ASAT and ALAT levels \< 2.5 normal values * Liver function: prothrombin level \> 70% * Liver function: fibrinogen \> 1.5 g/l * Renal function: creatinemia \< 1.5 normal value/age * Cardiac function: EF \> 60% and/or SF \> 30% * Signature of informed consent by patient if adolescent, by 2 parents or legal guardian if minor patient * For patients with childbearing potential, a contraceptive method is compulsory. This contraception must be continued 6 months after Myocet treatment end * For patients with childbearing potential, negative pregnancy test (betahCG test) Exclusion Criteria: * Non compliance with eligibility criteria * Severe or life-threatening infection * Non controlled evolutive or symptomatic intracranial hypertension * History of Myocet treatment, but patients could be treated with anthracyclines if cardiac function is normal * Hypersensibility to the active substance, to premixtures or one of excipients * Pregnancy and breastfeeding